Product
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes
1 clinical trial
18 indications
Indication
Adult Acute Lymphoblastic LeukemiaIndication
Recurrent B-Cell Non-Hodgkin LymphomaIndication
Recurrent Diffuse Large B-Cell LymphomaIndication
B-Cell Non-Hodgkin LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
High Grade B-Cell LymphomaIndication
B-cell lymphoma 2Indication
BCL6 RearrangementsIndication
Refractory High Grade B-Cell LymphomaIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
NOSIndication
Recurrent High Grade B-Cell LymphomaClinical trial
A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic LeukemiaStatus: Terminated, Estimated PCD: 2023-03-23